Dr. Victor Y. Yazbeck
Claim this profileVirginia Commonwealth University/Massey Cancer Center
Studies Lymphoma
Studies Mixed-Cell Lymphoma
9 reported clinical trials
21 drugs studied
Area of expertise
1Lymphoma
CD30 negative
HTLV-1 positive
Stage I
2Mixed-Cell Lymphoma
EZH2 negative
EZH2 positive
Affiliated Hospitals
Clinical Trials Victor Y. Yazbeck is currently running
Social and Genetic Factors
for Lymphoma Survivors
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood samples and health and treatment information from cancer survivors of Hodgkin or non-Hodgkin lymphoma may help doctors identify conditions that increase the likelihood of AYAs getting sick and dying after treatment of cancer and better understand how to address the needs of adolescent and young adult cancer survivors.
Recruiting1 award N/A10 criteria
Tazemetostat + Belinostat
for Lymphoma
This phase I trial tests the safety, side effects, and best dose of combination therapy with tazemetostat and belinostat in treating patients with lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Tazemetostat is in a class of medications called EZH2 inhibitors. The EZH2 gene provides instructions for making a type of enzyme called histone methyltransferase which is involved in gene expression and cell division. Blocking EZH2 may help keep cancer cells from growing. Belinostat is in a class of medications called histone deacetylase inhibitors. Histone deacetylases are enzymes needed for cell division. Belinostat may kill cancer cells by blocking histone deacetylase. It may also prevent the growth of new blood vessels that tumors need to grow and may help make cancer cells easier to kill with other anticancer drugs. There is some evidence in animals and in living human cells that combination therapy with tazemetostat and belinostat can shrink or stabilize cancer, but it is not known whether this will happen in people. This trial may help doctors learn more about treatment of patients with relapsed or refractory lymphoma.
Recruiting1 award Phase 1
More about Victor Y. Yazbeck
Clinical Trial Related13 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Victor Y. Yazbeck has experience with
- Brentuximab Vedotin
- Rituximab
- Venetoclax
- Cyclophosphamide
- Doxorubicin
- Prednisone
Breakdown of trials Victor Y. Yazbeck has run
Lymphoma
Mixed-Cell Lymphoma
Central Nervous System Hodgkin Lymphoma
Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Victor Y. Yazbeck specialize in?
Victor Y. Yazbeck focuses on Lymphoma and Mixed-Cell Lymphoma. In particular, much of their work with Lymphoma has involved CD30 negative patients, or patients who are HTLV-1 positive.
Is Victor Y. Yazbeck currently recruiting for clinical trials?
Yes, Victor Y. Yazbeck is currently recruiting for 2 clinical trials in Richmond Virginia. If you're interested in participating, you should apply.
Are there any treatments that Victor Y. Yazbeck has studied deeply?
Yes, Victor Y. Yazbeck has studied treatments such as Brentuximab Vedotin, Rituximab, Venetoclax.
What is the best way to schedule an appointment with Victor Y. Yazbeck?
Apply for one of the trials that Victor Y. Yazbeck is conducting.
What is the office address of Victor Y. Yazbeck?
The office of Victor Y. Yazbeck is located at: Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia 23298 United States. This is the address for their practice at the Virginia Commonwealth University/Massey Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.